Literature DB >> 29505548

Concomitant endometrial and cervical adenocarcinoma: A case report and literature review.

Mengfei Xu1, Feng Zhou, Lili Huang.   

Abstract

RATIONALE: Concomitant malignancy of the endometrium and cervix is extremely rare. PATIENT CONCERNS: A 56-year-old female presented to the Women's Hospital, School of Medicine, Zhejiang University, complaining of irregular vaginal bleeding. The human papillomavirus test (type 18/45) was positive. We performed dilation and curettage; pathology revealed moderately differentiated endometrial carcinoma exhibiting squamous differentiation. The epithelium of the cervical uterus was atypical upon biopsy. DIAGNOSES: Histological and immunochemical tests confirmed a diagnosis of endometrial carcinoma concomitant with cervical adenocarcinoma.
INTERVENTIONS: She underwent laparoscopic staging surgery. OUTCOMES: The patient fully recovered with only surgery. LESSONS: Endometrial carcinoma concomitant with cervical adenocarcinoma is very rare. It is imperative to schedule adequate examination, and to perform careful preoperative diagnosis and appropriate treatment to minimize relapse.
Copyright © 2017 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29505548      PMCID: PMC5943103          DOI: 10.1097/MD.0000000000009596

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


Introduction

Concomitant primary malignant tumors of the female genital tract are rare. Most such cases are combined endometrial and ovarian cancer[ of unknown etiology and pathogenesis. It has been suggested that when embryologically similar tissues are concomitantly exposed to carcinogens or irritants, synchronous neoplasms may develop.[ In addition, the expression of the p53 tumor suppressor gene may increase the risk of a secondary tumor.[ We present a rare case of concomitant malignancy of the endometrium and cervix.

Case report

A 56-year-old female (gravidity 2; parity 2) with no significant medical history or any physical finding other than irregular vaginal bleeding presented to us for careful evaluation. Menopause had commenced at the age of 54 years. Physical examination revealed a soft abdomen, cervical atrophy, no contact bleeding, and no tenderness on palpation of the bilateral adnexa. The serum levels of carbohydrate antigen (CA)125, CA199, alpha-fetoprotein, and carcinoembryonic antigen were all within normal limits. The human papillomavirus (HPV) test (type 18/45) was positive. We performed dilation and curettage; pathology revealed a moderately differentiated endometrial carcinoma accompanied by squamous differentiation in the uterine cavity. The epithelium of the cervical uterus was atypical upon biopsy. We scheduled laparoscopic staging surgery including radical hysterectomy, bilateral adnexectomy, and pelvic lymphadenectomy. No dispersal of a malignant endometrial tumor was observed in the abdominal cavity. Both the pelvic and periaortic lymph nodes were normal when palpated. Macroscopically, the uterus was approximately 7.5 × 4.5 × 3 cm in dimension; an endometrial tumor 1.2 × 1.0 × 0.5 cm in dimension was evident in the uterine cavity. On cutting, the tumor surface was predominantly solid in nature and gray in color, accompanied by obvious hemorrhage and necrosis, and invaded the superficial myometrium. No cervical mass was apparent. The bilateral adnexa were macroscopically normal. Microscopically, the uterine cavity mass exhibited areas of crowded, complex, branching glandular structures, lined by stratified columnar epithelium. The extent of nuclear atypia was only moderate; the cytoplasm was eosinophilic and granular. Elsewhere, focal squamous differentiation was apparent. Histologically, the cervical pattern was complex; atypical neoplastic glands invaded the stroma. The neoplastic epithelium contained atypical neoplastic glands with enlarged, elongated hyperchromatic nuclei (Fig. 1). The cervical canal was normal, as were both fallopian tubes and ovaries. The pelvic lymph nodes were negative.
Figure 1

Microscopic photograph of endometrial and cervical adenocarcinoma. The endometrial carcinoma comprised crowded, complex, branching glandular structures (A 50×, B 100×, C 200×) with moderate uclear atypia (D 400×). The cervical adenocarcinoma invaded the stroma (E 50×, F 100×). The neoplastic epithelium contained atypical neoplastic glands (G 200×) with enlarged, elongated hyperchromatic nuclei (H 400×).

Microscopic photograph of endometrial and cervical adenocarcinoma. The endometrial carcinoma comprised crowded, complex, branching glandular structures (A 50×, B 100×, C 200×) with moderate uclear atypia (D 400×). The cervical adenocarcinoma invaded the stroma (E 50×, F 100×). The neoplastic epithelium contained atypical neoplastic glands (G 200×) with enlarged, elongated hyperchromatic nuclei (H 400×). Immunohistochemically, the tumor in the uterine cavity was positive for the estrogen receptor (ER), progesterone receptor (PR), and vimentin; and was partial positive for p16, with a high ki67 index. However, the tumor in the uterine was diffusely positive for p16, but was negative for ER, PR, and vimentin (Fig. 2). Thus, we diagnosed the patients with endometrial carcinoma (Grade 2) concomitant with cervical adenocarcinoma (of the usual type).
Figure 2

The immunochemical photograph of endometrial and cervical adenocarcinoma. P63 (A, F 200×), vimentin (B, G 200×), ER (C, H 200×), PR (D, I 200×), Ki67 (E, J 200×) stained in the tumor cells of endometrial adenocarcinoma (A–E). The different staining pattern was observed in the neoplastic glands of cervix (F–J). ER = estrogen receptor, PR = progestrogen receptor.

The immunochemical photograph of endometrial and cervical adenocarcinoma. P63 (A, F 200×), vimentin (B, G 200×), ER (C, H 200×), PR (D, I 200×), Ki67 (E, J 200×) stained in the tumor cells of endometrial adenocarcinoma (A–E). The different staining pattern was observed in the neoplastic glands of cervix (F–J). ER = estrogen receptor, PR = progestrogen receptor.

Discussion

Tumors are defined as synchronous when they develop concomitantly. Synchronous primary genital cancers are rare, constituting only 1% to 6% of all genital tract neoplasms.[ Single neoplasms or metastatic tumors of the cervix, endometrium, or ovary are more common. To date, only 6 cases of concomitant endometrial and cervical cancer have been reported.[ We report a case of mixed endometrial carcinoma in a 56-year-old female, accompanied by cervical adenocarcinoma, which is unusual. Patients with endometrial cancer are at markedly higher risk of concomitant breast, fallopian tube, ovarian, cervical, and colon cancer.[ Accurate differential diagnosis of primary and metastatic tumors is essential, because both the treatment and outcomes significantly differ. The treatment strategy depends on age, initial cancer stage and grade, the extent of myometric lymphatic invasion, and lymphatic metastasis status. Tumor staging is the most important factor when evaluating the prognosis of endometrial cancer. FIGO recommends that when endometrial carcinoma attains the cervix, the cancer should be staged as II.[ The standard treatment for endometrial cancer is hysterectomy, bilateral salpingo-oophorectomy, and further surgical staging. Grade 1 or 2 cancers with minimal myometrial infiltration are low risk, and no treatment is required. Those with suspected cervical stromal invasion and lymphovascular involvement may require adjuvant radiation therapy.[ Malignant cervical glandular lesions are less common than squamous cell carcinoma, and are difficult to diagnose upon routine inspection.[ Although the tumor may attain the uterine cavity, neither tumor staging (IB1) nor prognosis is affected. Both the optimal treatment for cervical adenocarcinoma and prognosis remain unclear. Radical hysterectomy has been recommended for those with stage IB1 cervical cancer.[ Patients with high-level risk factors require extensive adjuvant radiotherapy. Most reported contemporaneous primary neoplasms are of early stage and low-grade, as in our case.[ Many studies have shown that patients with contemporaneous early/low-grade endometrial and ovarian carcinomas survive better than those with more advanced metastatic malignancies.[ One patient with both endometrial and cervical cancer exhibited no recurrence over 2 years of follow-up after comprehensive treatment. If preoperative diagnosis of a cervical glandular lesion fails, radiotherapy after surgery is required as rescue treatment[ However, the origin of the tumor of our present case remains debatable because of the histological features. In endometrial cancer, ER status may be the predominant element increasing the underlying risk for multiple cancers, whereas HPV is associated with the development of cervical and vaginal lesions.[ The expression of ER, PR, and vimentin indicated that the tumor was of endometrial origin. However, the absence of hormone receptors from the cervix accompanied by diffuse p16 reactivity favored a cervical origin. Moreover, the low-grade histology indicated a multifocal, primary sporadic cancer. Therefore, we considered that the patient had contemporaneous malignancies of the endometrium and cervix.

Conclusion

In conclusion, our patient had independent primary endometrial and cervical tumors distinguishable both clinicopathologically and immunohistochemically. Concomitant primary gynecological cancers are uncommon; thus, more case reports are required to define the most appropriate treatment.
  13 in total

1.  Synchronous occurrence of primary neoplasms of the uterus with mucinous carcinoma of the cervix and endometrioid carcinoma of the endometrium.

Authors:  Hsu-Dong Sun; Chung-Ru Lai; Ming-Shyen Yen; Peng-Hui Wang
Journal:  Taiwan J Obstet Gynecol       Date:  2011-09       Impact factor: 1.705

2.  Clinical analysis of synchronous primary neoplasms of the female reproductive tract.

Authors:  Seo-Yun Tong; Yong-Sek Lee; Jong-Sup Park; Seog-Nyeon Bae; Jun-Mo Lee; Seung-Eun Namkoong
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2006-10-17       Impact factor: 2.435

3.  Multifocal disease in the upper genital canal.

Authors:  J D Woodruff; D Solomon; H Sullivant
Journal:  Obstet Gynecol       Date:  1985-05       Impact factor: 7.661

4.  Simultaneously detected endometrial and ovarian carcinomas--a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study.

Authors:  R Zaino; C Whitney; M F Brady; K DeGeest; R A Burger; R E Buller
Journal:  Gynecol Oncol       Date:  2001-11       Impact factor: 5.482

5.  The relation between cancer incidence among relatives and the occurrence of multiple primary carcinomas following head and neck cancer.

Authors:  V Bongers; B J Braakhuis; H Tobi; H Lubsen; G B Snow
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1996-08       Impact factor: 4.254

6.  Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.

Authors:  Jorge P Orezzoli; Stefano Sioletic; Alexander Olawaiye; Esther Oliva; Marcela G del Carmen
Journal:  Gynecol Oncol       Date:  2009-04-05       Impact factor: 5.482

7.  Synchronous primary carcinoma in 5 different organs of a female genital tract: an unusual case and review of the literature.

Authors:  Melahat Atasever; Bulent Yilmaz; Gulay Dilek; Eda Yilmaz Akcay; Sefa Kelekci
Journal:  Int J Gynecol Cancer       Date:  2009-05       Impact factor: 3.437

8.  Second primary genital malignancies associated with endometrial cancer.

Authors:  G Ohel; Z Schwartz; A Birkenfeld; S O Anteby; J G Schenker
Journal:  Arch Gynecol       Date:  1986

Review 9.  New developments in endocervical glandular lesions.

Authors:  W Glenn McCluggage
Journal:  Histopathology       Date:  2012-11-08       Impact factor: 5.087

Review 10.  Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases.

Authors:  Pamela T Soliman; Brian M Slomovitz; Russell R Broaddus; Charlotte C Sun; Jonathan C Oh; Patricia J Eifel; David M Gershenson; Karen H Lu
Journal:  Gynecol Oncol       Date:  2004-08       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.